The winners over the next five years” will be the companies that “fully integrate” artificial intelligence into drug ...

Is On Investors’ Radar Today Recursion Pharmaceuticals (RXRX) shares recently closed at US$3.98, with the stock showing a negative return over the past month and past 3 months, which may prompt ...

OpenAI is now openly saying that its latest coding system helped build itself, a milestone that shifts the debate from how ...

The spotlight is now firmly on clinical validation for Exscientia following its merger with Recursion Pharmaceuticals. The company’s core artificial intelligenc ...

The new coding model released Thursday afternoon, entitled GPT-5.3-Codex, builds on OpenAI’s GPT-5.2-Codex model and combines insights from the AI company’s GPT-5.2 model, which excels on non-coding ...

Canopy Network has announced it is launching Canopy Templates, a new blockchain building tool designed to aid in AI-assisted development.

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.9, denoting a -4.88% move from the preceding trading day.

As AI systems increasingly control life-and-death decisions--from autonomous vehicles to medical diagnostics to financial markets--a ...

-- VectorCertain introduces MRM-CFS, ultra-compact AI models for improved safety in edge cases. -- Existing AI systems fail on rare events; MRM-CFS offers precise detection and fusion solutions. -- ...

Discover the world of Recursive Self-Improvement (RSI) in AI. From I.J. Good's intelligence explosion to modern self-healing code and clinical applications, explore who is developing it, how it works, ...

Romanian startups exceeded expectations in 2025, registering an influx of capital and signaling a shift in the local sector.  The growth of last year was backed by international investors such as ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.32, marking a -3.36% move from the previous day.